phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion (vol 10, pg 28, 2012)

被引：0
|
作者：
Hamilton, Erika [1 ]
Blackwell, Kimberly [1 ]
Hobeika, Amy C. [2 ]
Clay, Timothy M. [3 ]
Broadwater, Gloria [4 ]
Ren, Xiu-Rong [5 ]
Chen, Wei [5 ]
Castro, Henry [3 ]
Lehmann, Frederic [3 ]
Spector, Neil [1 ]
Wei, Junping [6 ]
Osada, Takuya [6 ]
Lyerly, H. Kim [2 ]
Morse, Michael A. [1 ]
机构：
[1] Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Dept Surg, Div Gen Surg, Durham, NC 27710 USA
[3] GlaxoSmithKline Biol, Rixensart, Belgium
[4] Duke Canc Inst, Canc Stat Ctr, Durham, NC USA
[5] Duke Univ, Med Ctr, Dept Med, Div Gastroenterol, Durham, NC 27710 USA
[6] Duke Univ, Med Ctr, Dept Surg, Div Surg Sci, Durham, NC 27710 USA
来源：
JOURNAL OF TRANSLATIONAL MEDICINE | 2013年 / 11卷
关键词：
D O I：
10.1186/1479-5876-11-82
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
[No abstract available]
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Erratum to: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
    Erika Hamilton
    Kimberly Blackwell
    Amy C Hobeika
    Timothy M Clay
    Gloria Broadwater
    Xiu-Rong Ren
    Wei Chen
    Henry Castro
    Frederic Lehmann
    Neil Spector
    Junping Wei
    Takuya Osada
    H Kim Lyerly
    Michael A Morse
    Journal of Translational Medicine, 11
  • [2] Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
    Erika Hamilton
    Kimberly Blackwell
    Amy C Hobeika
    Timothy M Clay
    Gloria Broadwater
    Xiu-Rong Ren
    Wei Chen
    Henry Castro
    Frederic Lehmann
    Neil Spector
    Junping Wei
    Takuya Osada
    H Kim Lyerly
    Journal of Translational Medicine, 10
  • [3] Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
    Hamilton, Erika
    Blackwell, Kimberly
    Hobeika, Amy C.
    Clay, Timothy M.
    Broadwater, Gloria
    Ren, Xiu-Rong
    Chen, Wei
    Castro, Henry
    Lehmann, Frederic
    Spector, Neil
    Wei, Junping
    Osada, Takuya
    Lyerly, H. Kim
    JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10
  • [4] Beamion LUNG-1, a Phase Ia/Ib trial of the HER2-specific tyrosine kinase inhibitor, zongertinib (BI 1810631), in patients with HER2-driven tumors: outcomes according to HER2 aberration type
    Berz, D.
    Heymach, J.
    Opdam, F.
    Barve, M.
    Tu, H.
    Wu, Y.
    Mueller, A. M.
    Schroeter, L.
    Sadrolhefazi, B.
    Yoh, K.
    Yamamoto, N.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2024, 162 : S127 - S127
  • [5] HER2 shedding and serum HER2 extracellular domain: Biology and clinical utility in breast cancer (vol 38, pg 133, 2012)
    Tse, Chantal
    Gauchez, Anne-Sophie
    Jacot, William
    Lamy, Pierre-Jean
    CANCER TREATMENT REVIEWS, 2013, 39 (07) : 831 - 831
  • [6] A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis (vol 23, pg 1722, 2015)
    Leung, Kin-Mei
    Batey, Sarah
    Rowlands, Robert
    Isaac, Samine J.
    Jones, Phil
    Drewett, Victoria
    Carvalho, Joana
    Gaspar, Miguel
    Weller, Sarah
    Medcalf, Melanie
    Wydro, Mateusz M.
    Pegram, Robert
    Mudde, Geert C.
    Bauer, Anton
    Moulder, Kevin
    Woisetschlaeger, Max
    Tuna, Mihriban
    Haurum, John S.
    Sun, Haijun
    MOLECULAR THERAPY, 2015, 23 (11) : 1794 - 1794
  • [7] Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma
    Mason, Nicola J.
    Gnanandarajah, Josephine S.
    Engiles, Julie B.
    Gray, Falon
    Laughlin, Danielle
    Gaurnier-Hausser, Anita
    Wallecha, Anu
    Huebner, Margie
    Paterson, Yvonne
    CLINICAL CANCER RESEARCH, 2016, 22 (17) : 4380 - 4390
  • [8] Beamion LUNG-1, a phase Ia/Ib trial of the HER2-specific tyrosine kinase inhibitor, zongertinib (BI 1810631), in patients with HER2driven tumours: outcomes according to HER2 aberration type in lung and other tumours
    Feuersinger, A.
    Opdam, F.
    Heymach, J.
    Barve, M.
    Tu, H.
    Wu, Y.
    Berz, D.
    Mueller, A. M.
    von Wangenheim, U.
    Serra, J.
    Yoh, K.
    Yamamoto, N.
    VIRCHOWS ARCHIV, 2024, 485 : S425 - S426
  • [9] Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial
    Hegde, Meenakshi
    Navai, Shoba
    DeRenzo, Christopher
    Joseph, Sujith K.
    Sanber, Khaled
    Wu, Mengfen
    Gad, Ahmed Z.
    Janeway, Katherine A.
    Campbell, Matthew
    Mullikin, Dolores
    Nawas, Zeid
    Robertson, Catherine
    Mathew, Pretty R.
    Zhang, Huimin
    Mehta, Birju
    Bhat, Raksha R.
    Major, Angela
    Shree, Ankita
    Gerken, Claudia
    Kalra, Mamta
    Chakraborty, Rikhia
    Thakkar, Sachin G.
    Dakhova, Olga
    Salsman, Vita S.
    Grilley, Bambi
    Lapteva, Natalia
    Gee, Adrian
    Dotti, Gianpietro
    Bao, Riyue
    Salem, Ahmed Hamed
    Wang, Tao
    Brenner, Malcolm K.
    Heslop, Helen E.
    Wels, Winfried S.
    Hicks, M. John
    Gottschalk, Stephen
    Ahmed, Nabil
    NATURE CANCER, 2024, 5 (06) : 880 - 894
  • [10] HER2-specific Affibody Molecule [99mTc]Tc-ZHER2:41071: phase I clinical trial
    Tolmachev, Vladimir
    Bragina, Olga
    Chernov, Vladimir
    Larkina, Maria
    Rybina, Anastasiya
    Zelchan, Roman
    Oroujeni, Maryam
    Loftenius, Annika
    Orlova, Anna
    Sorensen, Jens
    Frejd, Fredrik
    NUCLEAR MEDICINE AND BIOLOGY, 2023, 126 : S197 - S198
12345